By Dr Nikola Mitrev

Journal articles

Karimi N; Moore AR; Jones A; Lukin A; Pipicella JL; Williams AJ; Ng W; Kanazaki R; Kariyawasam V; Mitrev N; Pandya K; Andrews JM; Connor SJ, 2025, 'On being on the same page: Predictors of gastroenterologist-patient misalignment in inflammatory bowel disease', Patient Education and Counseling, 130, http://dx.doi.org/10.1016/j.pec.2024.108487

Huang D; Rennie M; Krasovec A; Nagubandi S; Liu S; Ge E; Khehra B; Au M; Sivagnanam S; Kwan V; Rogge C; Mitrev N; Kariyawasam V, 2024, 'Impact of cytomegalovirus on outcomes in acute severe ulcerative colitis: a retrospective observational study', Therapeutic Advances in Chronic Disease, 15, http://dx.doi.org/10.1177/20406223241233203

Karimi N; Lukin A; Moore AR; Pipicella JL; Kanazaki R; Williams AJ; Ng W; Kariyawasam V; Mitrev N; Pandya K; Connor SJ, 2023, 'Adolescents and young adults communicating with gastroenterologists: Variation in inflammatory bowel disease clinical communication', International Journal of Adolescent Medicine and Health, 35, pp. 347 - 361, http://dx.doi.org/10.1515/ijamh-2023-0078

An YK; Lindsay N; Allan N; Khoo E; Fernandes R; Amiss A; Pham H; Wong KF; Ooi SY; Thin L; Lightowler D; Connor SJ; Williams AJ; De Cruz P; Li Wai Suen C; Kariyawasam V; Mitrev N; Ghaly S; Andrews JM; Christensen B; Sparrow MP; White LS; Bryant RV; Ding N; Leong R; Van Langenberg D; Seltenreich H; Subramaniam K; Radford-Smith G; Begun J, 2023, 'P663 Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn’s disease patients: results from the AURORA Study including ANZIBDC Cohort', Journal of Crohn's and Colitis, 17, pp. i793 - i794, http://dx.doi.org/10.1093/ecco-jcc/jjac190.0793

Kariyawasam VC; Mourad FH; Mitrev N; Paramsothy S; Selinger CP; Katelaris PH; Jones B; McDonald C; Barr G; Chapman G; Cowlishaw J; Andrews J; Leong RW, 2021, 'Early thiopurine maintenance is associated with reduced proximal disease progression and colectomy rate in ulcerative colitis', European Journal of Gastroenterology and Hepatology, 33, pp. 1524 - 1532, http://dx.doi.org/10.1097/MEG.0000000000002101

Mitrev N; Huang H; Hannah B; Kariyawasam VC, 2021, 'Review of exclusive enteral therapy in adult Crohn's disease', BMJ Open Gastroenterology, 8, http://dx.doi.org/10.1136/bmjgast-2021-000745

Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW, 2017, 'Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases', Alimentary Pharmacology and Therapeutics, 46, pp. 1037 - 1053, http://dx.doi.org/10.1111/apt.14368

Mitrev N; Kariyawasam V; Leong RW, 2017, 'Editorial: infliximab trough cut-off for perianal Crohn's disease – another piece of the therapeutic drug monitoring-guided infliximab dosing puzzle', Alimentary Pharmacology and Therapeutics, 45, pp. 1279 - 1280, http://dx.doi.org/10.1111/apt.14020

Mitrev N; Leong RW, 2017, 'Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease', Expert Opinion on Drug Safety, 16, pp. 303 - 317, http://dx.doi.org/10.1080/14740338.2017.1269169

Back to profile page